PunditScore
Pundits › M. V. Cunha
MC

M. V. Cunha

Compare →
Founder, MVC Investing
Investor-banker & operator-prognosticatorFinance

M. V. Cunha is a long-term investor and founder of MVC Investing, specializing in equity analysis with a focus on fundamental analysis and valuation. He holds a BSc in Economics and an MSc in Finance, and has been actively investing since early 2020, developing a concentrated portfolio strategy centered on high-conviction small-cap stocks.

No chart yet. A chart needs 8 resolved predictions, and M. has 4. The predictions themselves are below.

SORT
STILL OPEN
?
If in 2025 they converted 40% of incremental revenue into EBITDA, it’s hard to believe adj. EBITDA margins will only move from 2.5% to 3.5% in 2026.
Due Dec 31, 2026March 6, 2026FinanceEarningsPending
—
SCORE
⌄
?
Omada will have a strong start to 2027.
Due Mar 31, 2027August 8, 2026FinanceGrowthPending
—
SCORE
⌄
?
$OMDA could 5x from here
Due Oct 31, 2027October 2026stocksinvestmentPending
—
SCORE
⌄
?
Sign in to read this call.
own side · their own organization · shown, counts only if it does not happen
Due Dec 31, 2027December 11, 2025FinanceInvestingPending
—
SCORE
⌄
?
Current analyst estimates for 2028 EBITDA imply an adjusted EBITDA margin of ~6%, but based on my expectations it will likely be closer to 15%+.
Due Dec 31, 2028March 6, 2026FinanceEarningsPending
—
SCORE
⌄
?
Sign in to read this call.
Due Dec 31, 2028February 28, 2026pharmaceuticalproduct developmentPending
—
SCORE
⌄
?
Omada will not return to a negative bottom line from here.
August 8, 2026FinanceProfitabilityPending
—
SCORE
⌄
?
I expect expansions in the UK and Israel, and I wouldn’t be surprised to see a new data center built from scratch in Paris, France.
May 6, 2026ExpansionData CenterPending
—
SCORE
⌄
?
Sign in to read this call.
February 28, 2026pharmaceuticalinvestmentPending
—
SCORE
⌄
?
Sign in to read this call.
February 28, 2026pharmaceuticalproduct launchPending
—
SCORE
⌄
RESOLVED · NEWEST FIRST
◇
Omada will beat and raise guidance again next quarter.
August 8, 2026FinanceEarningsNo verdict
—
SCORE
⌄
✓
Nebius is set up for a clear revenue beat.
May 6, 2026call #3EarningsRevenueCorrect
30
SCORE
⌄
◇
I expect to see at least two or three new locations discussed in the upcoming report.
May 6, 2026CapacityExpansionToo vague to check
—
SCORE
⌄
✓
I would be surprised if we don’t see at least the two colocation sites announced this quarter.
May 6, 2026call #4CapacityColocationCorrect
97
SCORE
⌄
✓
Sign in to read this call.
November 9, 2025call #1EarningsNBISCorrect
30
SCORE
⌄
✓
Sign in to read this call.
November 9, 2025call #2EarningsPGYCorrect
63
SCORE
⌄

Still open · 10

THE FRONT EDGE

Not resolved, so they don’t move the score.

?
If in 2025 they converted 40% of incremental revenue into EBITDA, it’s hard to believe adj. EBITDA margins will only move from 2.5% to 3.5% in 2026.
Due Dec 31, 2026Said March 6, 2026FinanceEarnings
No market prices this claim
?
Omada will have a strong start to 2027.
Due Mar 31, 2027Said August 8, 2026FinanceGrowth
No market prices this claim
?
$OMDA could 5x from here
Due Oct 31, 2027Said October 2026stocksinvestment
No market prices this claim
?
Sign in to read this call.
Due Dec 31, 2027Said December 11, 2025FinanceInvesting
No market prices this claim
?
Current analyst estimates for 2028 EBITDA imply an adjusted EBITDA margin of ~6%, but based on my expectations it will likely be closer to 15%+.
Due Dec 31, 2028Said March 6, 2026FinanceEarnings
No market prices this claim
?
Sign in to read this call.
Due Dec 31, 2028Said February 28, 2026pharmaceuticalproduct development
No market prices this claim
?
Omada will not return to a negative bottom line from here.
Said August 8, 2026FinanceProfitability
No market prices this claim
?
I expect expansions in the UK and Israel, and I wouldn’t be surprised to see a new data center built from scratch in Paris, France.
Said May 6, 2026ExpansionData Center
No market prices this claim
?
Sign in to read this call.
Said February 28, 2026pharmaceuticalinvestment
No market prices this claim
?
Sign in to read this call.
Said February 28, 2026pharmaceuticalproduct launch
No market prices this claim